Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
0.1261
-0.0050 (-3.81%)
Oct 19, 2026, 11:38 AM EDT - Market open
Vivos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 20.9 | 17.44 | 15.03 | 13.8 | 16.02 | 16.89 | |
Revenue Growth | 45.22% | 16.05% | 8.91% | -13.87% | -5.10% | 29.23% |
Cost of Revenue | 7.96 | 6.9 | 6.01 | 5.53 | 6.01 | 4.28 |
Gross Profit | 12.94 | 10.54 | 9.02 | 8.27 | 10.02 | 12.6 |
Selling, General & Admin | 33.7 | 29.13 | 19.61 | 24.95 | 34.18 | 31.34 |
Research & Development | - | - | - | - | 0.2 | - |
Operating Expenses | 35.49 | 30.44 | 20.19 | 25.57 | 35.05 | 32.08 |
Operating Income | -22.55 | -19.89 | -11.17 | -17.3 | -25.03 | -19.47 |
Interest Expense | -2.2 | - | - | - | - | -0.01 |
Other Non Operating Income (Expenses) | -1.27 | -1.34 | 0.04 | 3.71 | -0.1 | 0.11 |
EBT Excluding Unusual Items | -26.03 | -21.23 | -11.14 | -13.58 | -25.13 | -19.38 |
Asset Writedown | - | - | - | - | - | -0.91 |
Other Unusual Items | 0.4 | - | - | - | 1.29 | - |
Pretax Income | -25.63 | -21.23 | -11.14 | -13.58 | -23.85 | -20.29 |
Earnings From Continuing Operations | -25.63 | -21.23 | -11.14 | -13.58 | -23.85 | -20.29 |
Minority Interest in Earnings | 0.17 | 0.06 | - | - | - | - |
Net Income | -25.46 | -21.17 | -11.14 | -13.58 | -23.85 | -20.29 |
Net Income to Common | -25.46 | -21.17 | -11.14 | -13.58 | -23.85 | -20.29 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 14 | 10 | 5 | 1 | 1 | 1 |
Shares Outstanding (Diluted) | 14 | 10 | 5 | 1 | 1 | 1 |
Shares Change | 72.97% | 104.66% | 311.68% | 32.46% | 8.39% | 65.00% |
EPS (Basic) | -1.83 | -2.06 | -2.22 | -11.14 | -25.90 | -23.89 |
EPS (Diluted) | -1.83 | -2.06 | -2.22 | -11.14 | -25.90 | -23.89 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -19.01 | -17.6 | -13.26 | -12.8 | -20.51 | -18.13 |
Free Cash Flow Per Share | -1.36 | -1.71 | -2.64 | -10.50 | -22.28 | -21.35 |
Gross Margin | 61.90% | 60.44% | 60.00% | 59.93% | 62.52% | 74.65% |
Operating Margin | -107.90% | -114.05% | -74.32% | -125.32% | -156.21% | -115.31% |
Profit Margin | -121.79% | -121.37% | -74.09% | -98.42% | -148.81% | -120.15% |
Free Cash Flow Margin | -90.96% | -100.92% | -88.21% | -92.74% | -128.00% | -107.38% |
EBITDA | -20.76 | -18.59 | -10.59 | -16.68 | -24.36 | -18.74 |
EBITDA Margin | -99.33% | -106.55% | -70.45% | -120.82% | -152.03% | -110.97% |
D&A For EBITDA | 1.79 | 1.31 | 0.58 | 0.62 | 0.67 | 0.73 |
EBIT | -22.55 | -19.89 | -11.17 | -17.3 | -25.03 | -19.47 |
EBIT Margin | -107.90% | -114.05% | -74.32% | -125.32% | -156.21% | -115.31% |
Revenue as Reported | 20.9 | 17.44 | 15.03 | 13.8 | 16.02 | 16.89 |